


STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2013														Rs. in lakhs
PART I	Particulars	Stand alone						Consolidated						
		Three months ended			Six months ended			Three months ended			Six months ended			
		30.09.2013	30.06.2013	30.09.2012	30.09.2012	30.09.2013	30.09.2012	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	Year Ended 31.03.2013	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from operations													
	(a) Net sales/ income from operations (Net of excise duty)	158,162	159,578	137,248	137,248	317,740	317,740	189,748	169,960	148,105	359,708	267,849	578,312	
	(b) Other operating income	1,638	1,596	1,879	1,879	3,234	3,234	1,638	1,596	1,939	3,234	3,636	7,219	
	Total income from operations (net)	159,800	161,174	139,127	139,127	320,974	320,974	191,386	171,556	150,044	362,942	271,485	585,531	
2	Expenses													
	(a) Cost of material consumed	80,838	79,559	80,547	80,547	160,397	160,397	85,166	78,693	75,052	163,859	131,887	309,144	
	(b) Purchase of stock-in-trade	429	1,884	1,502	1,502	2,313	2,313	2,838	5,173	11,995	8,011	25,652	16,958	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,855	5,658	(2,684)	(2,684)	7,513	7,513	3,917	5,262	(11,396)	9,179	(17,150)	(27,025)	
	(d) Employee benefits expense	11,964	12,346	10,809	10,809	24,310	24,310	19,596	18,891	16,703	38,487	32,130	66,331	
	(e) Depreciation and amortisation expense	4,703	4,593	4,213	4,213	9,296	9,296	7,662	7,192	5,983	14,854	11,867	24,874	
	(f) Provision for decline in the value of long-term investment	2,500	-	1,800	1,800	2,500	2,500	-	-	-	-	-	-	
	(g) Other expenses	26,185	24,901	23,431	23,431	51,086	51,086	36,034	32,766	32,662	68,800	59,963	131,216	
	Total expenses	128,474	128,941	119,618	119,618	257,415	257,415	155,213	147,977	130,999	303,190	244,349	521,498	
3	Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	31,326	32,233	19,509	19,509	63,559	63,559	36,173	23,579	19,045	59,752	27,136	64,033	
4	Other Income	205	287	622	622	492	492	511	392	659	903	881	2,854	
5	Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)	31,531	32,520	20,131	20,131	64,051	64,051	36,684	23,971	19,704	60,655	28,017	66,887	
6	Finance costs (refer note 6)	1,969	2,073	2,999	2,999	4,042	4,042	2,458	2,539	3,350	4,997	6,661	13,133	
7	Foreign exchange (Gain)/ Loss (refer note 6)	7,838	13,953	(12,485)	(12,485)	21,791	21,791	6,829	17,241	(11,767)	24,070	8,878	16,344	
8	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	21,724	16,494	29,617	29,617	38,218	38,218	27,397	4,191	28,121	31,588	12,478	37,410	
9	Exceptional item	-	-	-	-	-	-	-	-	12	-	12	-	
10	Profit/(Loss) from ordinary activities before tax (8-9)	21,724	16,494	29,617	29,617	38,218	38,218	27,397	4,191	28,109	31,588	12,466	37,410	
11	Tax expense /(credit)	3,754	2,131	5,816	5,816	5,885	5,885	4,011	2,445	5,913	6,456	3,173	8,271	
12	Net Profit/(Loss) for the period (10-11)	17,970	14,363	23,801	23,801	32,333	32,333	23,386	1,746	22,196	25,132	9,293	29,139	
13	Minority Interest	-	-	-	-	-	-	(109)	(114)	(39)	(223)	(51)	(246)	
14	Net Profit/(Loss) after taxes and minority interest (12-13)	17,970	14,363	23,801	23,801	32,333	32,333	23,495	1,860	22,235	25,355	9,344	29,385	
15	Paid-up Equity Share Capital (Face value Re. 1 per share)	2,912	2,912	2,911	2,911	2,912	2,912	2,912	2,912	2,912	2,912	2,912	2,912	
16	Reserves excluding Revaluation Reserve	-	-	-	-	-	-	-	-	-	-	-	-	
17	Earnings per share of Re.1/- each (not annualised)													
	(a) Basic	6.17	4.93	8.17	8.17	11.10	11.10	8.07	0.64	7.64	8.71	3.21	10.09	
	(a) Diluted	6.16	4.93	8.17	8.17	11.09	11.09	8.06	0.64	7.64	8.70	3.21	10.09	



PART II SELECT INFORMATION FOR THE QUARTER & HALF YEAR ENDED 30.09.2013							
	Particulars	Three months ended			Six months ended		
		30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	Year Ended 31.03.2013
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding	131,514,694	131,514,694	131,708,307	131,514,694	131,708,307	131,514,844
	- Number of Shares	45.16	45.16	45.24	45.16	45.24	45.16
	- Percentage of Shareholding						
2	Promoters and promoter group Shareholding	33,293,797	30,005,297	34,300,902	33,293,797	34,300,902	37,461,297
	a) Pledged/ Encumbered						
	- Number of Shares						
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	20.85	18.79	21.52	20.85	21.52	23.46
	- Percentage of Shares (as a % of the total share capital of the company)	11.43	10.30	11.78	11.43	11.78	12.86
	b) Non-encumbered						
	- Number of Shares	126,402,799	129,691,299	125,112,081	126,402,799	125,112,081	122,235,149
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	79.15	81.21	78.48	79.15	78.48	76.54
	- Percentage of Shares (as a % of the total share capital of the company)	43.41	44.54	42.98	43.41	42.98	41.97

	Particulars	Three months ended 30.09.2013
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	53
	Disposed of during the quarter	53
	Remaining unresolved at the end of the quarter	Nil



NOTES:

- 1 The above unaudited financial results for the quarter and six months ended September 30, 2013 as reviewed by the Audit Committee have been approved by the Board at its meeting held on November 7, 2013. A Limited Review of the stand alone financial results for the quarter ended September 30, 2013 has been carried out by the Statutory Auditors.
- 2 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Venture.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs.122,642 lakhs(Quarter ended September 30, 2012: Rs.104,778 lakhs).
- 5 Net sales for the current quarter include dossier income in standalone of Rs.392 lakhs (Quarter ended September 30, 2012:Rs.428 lakhs) and in consolidated of Rs.625 lakhs (Quarter ended September 30, 2012: Rs.1166 lakhs).
- 6 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.4,920 lakhs, Rs.5,048 lakhs Rs.4,669 lakhs for three months ended September 30, 2013, June 30, 2013, September 30, 2012, respectively and Rs.9,968 lakhs, Rs.9,445 lakhs for the six months ended September 30, 2013 and September 30, 2012 respectively and Rs.13,532 lakhs for the year ended March 31, 2013 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 7 With effect from April 1, 2013, the Company has changed the accounting policy for valuation of cost of the inventory from 'first-in-first-out' basis to 'moving average basis'. Accordingly, this has resulted in decrease in the value of inventory on standalone basis as at September 30, 2013 and June 30, 2013 by Rs. 694 lakhs and Rs. 60 lakhs respectively, and on consolidated basis by Rs.713 lakhs and Rs. 158 lakhs respectively, and decrease in profit before tax on standalone basis for the quarter ended June 30, 2013 and September 30, 2013, and for the six months ended September 30, 2013 by Rs. 60 lakhs, Rs. 634 lakhs and Rs. 694 lakhs respectively, and on consolidated basis for the quarter ended June 30, 2013 and September 30, 2013, and for the six months ended September 30, 2013 by Rs. 44 lakhs Rs.554 lakhs and Rs. 598 lakhs respectively.
- 8 During the October, 2013 Hyacinths Pharma Pvt.Ltd., and Silicon Life Sciences Pvt.Ltd., have become a wholly owned subsidiary of the Company. During the quarter Aurobindo Pharma (Poland) Sp.z.o.o. and Aurobindo Switzerland AG, the step down subsidiaries of the Company have been liquidated
- 9 The Board has approved an interim dividend @125% i.e. Rs1.25(Rupee One and paise twenty five only) per equity share of Re1/(Rupee One only) for the year 2013-14.
- 10 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board


N. Govindarajan
Managing Director



Place: Hyderabad

Date : November 7, 2013

www.aurobindo.com

Rs. In lakhs

Statement of Assets and Liabilities

	Particulars	Stand alone		Consolidated	
		As At 30.09.2013 Un audited	As At 31.03.2013 Audited	As At 30.09.2013 Un audited	As At 31.03.2013 Audited
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	(a) Share capital	2,912	2,912	2,912	2,912
	(b) Reserves and surplus	319,074	290,998	290,047	257,665
	Sub-total - Shareholders' funds	321,986	293,910	292,959	260,577
2	Share application money pending allotment	-	-	-	-
3	Minority interest	-	-	2,329	1,100
4	Non-current liabilities				
	(a) Long-term borrowings	108,535	104,106	119,435	114,826
	(b) Deferred tax liabilities (net)	12,679	6,794	12,686	6,800
	(c) Long-term provisions	934	850	987	900
	Sub-total - Non-current liabilities	122,148	111,750	133,108	122,526
5	Current liabilities				
	(a) Short-term borrowings	168,000	173,390	231,148	223,612
	(b) Trade payables	110,151	90,128	137,943	96,874
	(c) Other current liabilities	16,788	6,804	20,195	15,067
	(d) Short-term provisions	9,308	6,475	11,325	8,009
	Sub-total - Current liabilities	304,247	276,797	400,611	343,582
	TOTAL - EQUITY AND LIABILITIES	748,381	682,457	829,007	727,785
B	ASSETS				
1	Non-current assets				
	(a) Fixed assets	212,866	217,824	284,396	280,195
	(b) Goodwill on consolidation	-	-	8,842	5,544
	(c) Non-current investments	73,808	70,794	2,702	2,224
	(d) Deferred tax assets (net)	-	-	-	-
	(e) Long-term loans and advances	42,402	28,910	38,378	24,281
	(f) Other non-current assets	3,698	1,858	329	1,866
	Sub-total - Non-current assets	332,774	319,386	334,647	314,110
2	Current assets				
	(a) Current investments	4	4	4	4
	(b) Inventories	145,366	143,173	211,826	192,359
	(c) Trade receivables	222,633	173,059	203,023	159,698
	(d) Cash and cash equivalents	10,650	11,458	30,605	20,845
	(e) Short-term loans and advances	30,914	27,598	39,831	33,208
	(f) Other current assets	6,040	7,779	9,071	7,561
	Sub-total - Current assets	415,607	363,071	494,360	413,675
	TOTAL - ASSETS	748,381	682,457	829,007	727,785

